 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Prabhudas Lilladher recommended hold rating on Jubilant Ingrevia with a target price of Rs 433 in its research report dated November 02, 2023.

Hold Jubilant Ingrevia; target of Rs 433: Prabhudas Lilladher

Jubilant Ing. Standalone September 2023 Net Sales at Rs 1,003.09 crore, down 19.78% Y-o-Y

Jubilant Ingrevia has allotted commercial paper of Rs 100 crore on 08 September 2023. 

Jubilant Ingrevia allots commercial paper of Rs 100 cr 

Jubilant Ingrevia has redeemed commercial paper aggregating Rs 175 crore on 05 September 2023. 

Jubilant Ingrevia redeems commercial paper of Rs 175 cr 

CRISIL said that the rating continues to reflect the healthy business risk profile of JVL, supported by its leading market position across most products, vertically integrated operations, and diversified revenue profile across business segments, geographies and end-user industries; the rating also factors in the companys healthy financial risk profile. These strengths are partially offset by moderately large working capital requirement and exposure to fluctuations in input prices as well as government policies.Operating performance weakened in fiscal 2023, with revenues declining by 4% on-year to Rs. 4,773 crore, mainly due to weak demand in the nutrition and health solutions (NHS) segment due to the impact of avian and swine flu in certain key markets as well as fall in realisations in the NHS and chemical intermediates (CI) segments; while specialty chemicals (SC) segment grew at a healthy rate.For the first quarter of fiscal 2024, while performance of the NHS segment has improved, overall revenues declined 8% year-on-year due to lower demand from the agrochemical customers of the SC segment. However, CRISIL ratings expects the revenues to recover during the second half fiscal 2024.  Over the medium term, business prospects continue to remain comfortable with an annual revenue growth of 8-10% expected, supported by addition of new value-added products and the companys capacity expansion plans across the business segments.Operating margins declined to 11.5% in fiscal 2023 from 17.0% in fiscal 2022 due to sharp increase in the power and fuel cost (formed ~15% of the revenue in fiscal 2023). While operating margin remained low in the first quarter of fiscal 2024, it is expected to improve to 13-15% going forward driven by lower fuel cost and improved operating performance in the NHS segment.The financial risk profile remains comfortable, with a healthy networth of Rs 2,652 crore and gross debt of Rs 397 crore as on March 31, 2023. Debt protection metrics remained healthy with interest coverage of 26.9 times and net debt to earnings before interest, taxes, depreciation and amortisation (Ebitda) of 0.6 times in fiscal 2023. Financial profile is expected to remain stable over the medium term even after factoring in sizeable ongoing and planned capex over fiscals 2024 and 2025, which is to be funded prudently through mix of debt and internal accruals. Jubilant Ingrevia is a global integrated life science products and innovative solutions provider serving pharmaceutical, nutrition, agrochemical and industrial clients with customised products and solutions that are cost effective and conform to premium quality standards.The company reported 27.45% fall in consolidated net profit to Rs 57.59 crore on a 7.83% fall in sales to Rs 1,068.66 crore in Q1 FY24 over Q1 FY23.The scrip rose 0.24% to currently trade at Rs 519 on the BSE.

CRISIL reaffirms rating of Jubilant Ingrevia at 'A1+'

 Jubilant Ingrevia has received reaffirmation in credit rating for commercial paper (Rs 600 crore enhanced from Rs 400 crore) at CRISIL A1+ from CRISIL. 

Jubilant Ingrevia receives affirmation in credit rating for CP 

 Jubilant Ingrevia has redeemed commercial paper aggregating Rs 100 crore on maturity date i.e. 25 August 2023. 

Jubilant Ingrevia redeems commercial paper of Rs 100 cr 

 Jubilant Ingrevia has approved the proposal of raising of funds up to Rs. 600 crore by issuance of Commercial Paper. 

 Jubilant Ingrevia plans to raise Rs 600 cr via CP issuance 

Jubilant Ing. Consolidated June 2023 Net Sales at Rs 1,075.02 crore, down 7.79% Y-o-Y

Jubilant Ingrevia has issued commercial paper aggregating Rs 100 crore on 12 July 2023. 

Jubilant Ingrevia raises Rs 100 cr via CPs 

Jubilant Ingrevia Ltd. engages in the provision of life science products and solutions. The company operates through the following segments: Speciality Chemicals, Nutrition and Health Solutions, and Life Science Chemicals. The Speciality Chemicals segment manufactures pyridine and picolines, fine chemicals, and agro chemicals. The Nutrition and Health Solutions segment offers nutrition and health ingredients, as well as animal and human nutrition health solutions. The Life Science Chemicals segment includes acetyls and specialty ethanol. The company was founded in 2019 and is headquartered in Noida, India.

Watchers	191
52-Wk Low	350.45
52-Wk High	568.05

Market Cap	68.57B
Volume (M)	469,867.00
52-Wk High	568.05
52-Wk Low	350.45

JUBLINGREA.NSE Jubilant Ingrevia Ltd.

About

Feed

News

Sentiment

Fundamentals